An innovative cell analytics technology that can increase therapy manufacturing efficiency by 30% and therefore reduce costs for up to 400K UK patients per year

Cytomos是一家英国生物技术中小企业，其核心项目团队由Lindsay Fraser(CSO，研究/项目经理)、Gordon Sharp(CTO，仪器开发)、Tom Clayton(首席系统架构师，固件/软件开发)和Sevi Giakoumelou(项目和研究经理，研究开发)组成。遗传疾病和罕见疾病的细胞治疗成本可能令人震惊，从GB 40K到远远超过GB 100万，有些治疗将持续一生。这一水平的费用可能会让一些人无法负担医疗保健，并产生了对更有效的细胞和基因疗法的迫切需求，以确保个性化药物不受社会经济因素的限制。英国拥有世界上超过12%的细胞和基因疗法临床试验，为了提高效率，英国的生物制造技术路线图要求到2030年将制造成本降低90%，时间减少80%。现有的细胞疗法制造过程使用的技术在制造过程中不直接观察细胞，因此返回的信息有限。为了创建更有效的分析，Cytomos正在开发查看单个细胞细节的技术，使用电场创建一种具有自动化潜力的无标签、可扩展的解决方案，每年可使多达40万英国患者受益，解决医疗不平等问题。Cytomos的项目将使细胞治疗制造效率提高30%，并将患者成本降低高达20%。简化的制造流程将减少对环境的影响，并进一步提高患者的可用性。

Cytomos is a UK biotechnology SME with a core project team of Lindsay Fraser (CSO, Head of Research/Programme Manager), Gordon Sharp (CTO, Instrument Development), Tom Clayton (Lead System Architect, Firmware/Software Development) and Sevi Giakoumelou (Project and Research Manager, Research Development).The cost of cell therapy for genetic disorders and rare diseases can be staggering, ranging from £40K to well over £1M, with some treatments continuing for a lifetime. This level of expense can put care out of reach for some populations and has created an immediate and urgent need for more efficient cell and gene therapies to ensure that personalised medicine is not limited by socioeconomic factors. The UK is home to over 12% of the world's clinical trials for cell and gene therapy, and to increase efficiency, the UK's Biomanufacturing Technology Roadmap calls for a 90% reduction in manufacturing costs and an 80% reduction in time by 2030\.Existing cell therapy manufacturing processes use techniques that do not look directly at the cells during manufacture and thus return limited information. To create more effective analytics, Cytomos is developing technology that looks at the details of an individual cell, using electrical fields to create a label-free, scalable solution with automation potential that could benefit up to 400K UK patients per year, addressing healthcare inequality.Cytomos' project will increase cell therapy manufacturing efficiency by 30% and reduce patient costs by up to 20%. A streamlined manufacturing process will reduce environmental impact and further improve availability to patients.